https://www.selleckchem.com/pr....oducts/Tipifarnib(R1
The management of low-grade (grade II) oligodendrogliomas is still controversial, due to their rarity and long-term survival. According to recent WHO 2016 Classification of central nervous system tumors oligodendrogliomas are defined by the coexistence of molecular alterations, such as isocitrate dehydrogenase (IDH)1/2 mutations and 1p/19q codeletion. These tumors have better outcome and higher response to chemotherapy compared with diffuse astrocytomas. The association of radiotherapy and procarbazine, lomustine (CCNU), vin
Like
Comment
Share
